MorphoSys AG - American Depositary Shares (NQ:MOR)

18.96 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MorphoSys AG - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session ↗

December 16, 2022

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 16, 2022

Via Benzinga

MorphoSys AG: Financial Calendar 2023

November 28, 2022

Via ACCESSWIRE

MorphoSys Earnings Preview ↗

November 15, 2022

Via Benzinga

MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease

November 14, 2022

Via ACCESSWIRE

Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022

November 10, 2022

Via ACCESSWIRE

Why Adobe Shares Are Trading Higher; Here Are 31 Stocks Moving Premarket ↗

December 16, 2022

Gainers Minim, Inc. (NASDAQ: MINM) shares rose 66.5% to $0.2903 in pre-market trading after gaining over 10% on Thursday. Minim, last month, reported worse-than-expected results.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

December 16, 2022

We're starting off the final trading day this week with a look at the biggest pre-market stock movers to watch for Friday!

Via InvestorPlace

Guardant Health, Novavax And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗

December 16, 2022

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

MorphoSys Highlights Preliminary Data From Tulmimetostat Study Across Broad Array of Advanced Tumors ↗

October 28, 2022

Via Benzinga

MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs ↗

December 07, 2022

Via Benzinga

Is The Oil And Gas Bull Market Over? This 2X Leveraged ETF Inversely Tracks Exxon, Occidental And More ↗

December 05, 2022

The Direxion Daily S&P Oil & Gas Exp & Prod Bear 2X Shares (NYSE: DRIP) was surging Monday after the Group of Seven (G7) nations and the European Union agreed to put a price cap of

Via Benzinga

MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

November 16, 2022

From MorphoSys AG

Via Business Wire

Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers ↗

November 14, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

November 14, 2022

Monday saw 33 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

November 16, 2022

On Wednesday, 70 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 14, 2022

Gainers

Via Benzinga

Earnings Scheduled For November 16, 2022 ↗

November 16, 2022

Companies Reporting Before The Bell • Golden Ocean Group (NASDAQ:GOGL) is estimated to report earnings for its third quarter.

Via Benzinga

Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday ↗

November 14, 2022

U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗

November 15, 2022

Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus...

Via Benzinga

Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗

November 14, 2022

Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.

Via Benzinga

Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others ↗

November 14, 2022

Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map.

Via Investor's Business Daily

Facebook Stalls Portal & Smartwatch Projects, Visa Breaks Debit Card Tie Up With FTX, $3B Bitcoin Withdrawn From Crypto Exchanges: Top Stories Monday, Nov. 14 ↗

November 14, 2022

Reuters

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 14, 2022

Gainers Opiant Pharma (NASDAQ:OPNT) stock rose 118.3% to $20.74 during Monday's pre-market session. The market value of their outstanding shares is at $107.1 million. As per the press release, Q3...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

November 14, 2022

Welcome back and get ready for the week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday morning!

Via InvestorPlace

Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months ↗

November 14, 2022

Via Benzinga

Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus ↗

November 14, 2022

The major U.S. index futures are pointing to a moderately lower opening on Wall Street on Monday, as optimism following a tamer inflation data gives way to apprehension. The yield on the benchmark...

Via Benzinga

Why MorphoSys Shares Are Trading Lower By Around 32%; Here Are 30 Stocks Moving Premarket ↗

November 14, 2022

Via Benzinga

MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting

November 03, 2022

Via ACCESSWIRE

MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors

October 27, 2022

Via ACCESSWIRE

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.